SYRE compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

SYRESpyre Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

SYRESpyre Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SYRE

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±11.9%▼−0.23%×0.02

Q2 FY26±13.8%▼−0.56%×0.04

Q1 FY26±8.3%▲+2.72%×0.33

Feb 20 '26±12.0%▲+14.28%×1.19

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedSYRE realized, solidLLY realized, hatchedOne scale, both sides: full bar = 15%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

SYRESpyre Therapeutics, Inc.

103.80▲+7.46%· post 103.81

Mkt cap$9.9BRevenue—Revenue—

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

SYRESpyre Therapeutics, Inc.

LLYELI Lilly & Co

103.80▲+7.46%post 103.81

Price

1,360.90▼−0.28%post 1,358.90

$9.9B

Mkt cap

$1.2T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

SYRE103.80▲+7.46%vsLLY1,360.90▼−0.28%ClosedNov 6 '26